<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483561</url>
  </required_header>
  <id_info>
    <org_study_id>285-03</org_study_id>
    <secondary_id>P30CA036727</secondary_id>
    <secondary_id>UNMC-28503</secondary_id>
    <secondary_id>ZENECA-UNMC-28503</secondary_id>
    <nct_id>NCT00483561</nct_id>
  </id_info>
  <brief_title>Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy</brief_title>
  <official_title>A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
      such as etoposide, work in different ways to stop the growth of tumor cells, either by
      killing the cells or by stopping them from dividing. Giving gefitinib together with etoposide
      may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving gefitinib together with etoposide
      works in treating patients with advanced prostate cancer that did not respond to hormone
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the activity of gefitinib and etoposide, in terms of overall response rate, in
           patients with hormone-refractory advanced prostate cancer previously treated with
           docetaxel-based therapy.

      Secondary

        -  Determine the toxicity of this regimen in these patients.

        -  Determine whether related biomarkers can help predict response in patients treated with
           this regimen.

      OUTLINE: This is a nonrandomized study.

      Patients receive oral gefitinib once daily on days 1-28 and oral etoposide once daily on days
      1-14. Treatment repeats every 28 days in the absence of disease progression or unacceptable
      toxicity.

      Patients undergo blood sample collection at baseline and periodically during study for
      correlative studies. Blood samples are analyzed by enzyme-linked immunosorbent assays for
      biomarkers (e.g., VEGF, basic fibroblast growth factor, and anti-EGFR antibody titers) in
      order to determine whether one or more of these biomarkers can predict response.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left UNMC
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate as Measured by RECIST Criteria and PSA Criteria</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>If there is at least 1 response, then 7 additional patients will be enrolled. If there are 4 or more responders overall, then the combination will be considered active and warrant further study. Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>At every cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Gefitinib plus Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.
Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib plus etoposide</intervention_name>
    <description>Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).</description>
    <arm_group_label>Gefitinib plus Etoposide</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD1839</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Progressive disease after a prior docetaxel-based regimen OR failed a prior
             docetaxel-based regimen

          -  Hormone-refractory disease, meeting 1 of the following criteria:

               -  Radiologically measurable disease

               -  Prostate-specific antigen (PSA) progression* while on hormonal therapy (including
                  withdrawal from a direct antagonist) NOTE: *If the confirmatory PSA value is less
                  than the screening PSA value, then an additional test for rising PSA is required
                  to document progression

          -  Must have underwent prior surgical castration OR currently be on a luteinizing
             hormone-releasing hormone agonist

        PATIENT CHARACTERISTICS:

          -  ANC &gt; 1,500/mm³

          -  Platelet count &gt; 100,000/mm³

          -  Hemoglobin &gt; 10 g/dL (in the absence of packed red blood cell transfusions within the
             past 4 weeks)

          -  Creatinine &lt; 2 mg/dL

          -  AST and ALT &lt; 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase &lt; 2 times ULN

          -  Fertile patients must use effective double-method contraception during and for 1 month
             after completion of study treatment

          -  No other malignancy within the past 5 years except basal cell carcinoma

          -  No clinically significant New York Heart Association class II-IV cardiovascular
             disease

          -  No evidence of severe or uncontrolled systemic disease (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  No unresolved chronic toxicity &gt; grade 2 from prior anticancer therapy, with the
             exception of alopecia

          -  No other significant clinical disorder or laboratory finding that would preclude study
             participation

          -  No known severe hypersensitivity to gefitinib or any of the excipients of this product

          -  No evidence of clinically active interstitial lung disease

               -  Patients with chronic, stable radiographic changes who are asymptomatic are
                  eligible

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior cytotoxic therapy

          -  At least 4 weeks since prior direct antagonists, including flutamide and nilutamide

          -  At least 6 weeks since prior bicalutamide

          -  At least 30 days since prior nonapproved or investigational drugs

          -  More than 4 weeks since prior palliative radiotherapy

               -  The irradiated lesion must not be used to assess response rate

          -  No prior gefitinib or etoposide

          -  No concurrent palliative radiotherapy

          -  No concurrent chemotherapeutic agents

          -  No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or Hypericum
             perforatum (St. John's wort)

          -  No concurrent hormones except antiandrogen therapy, steroids for adrenal failure,
             hormones for nondisease-related conditions (e.g., insulin for diabetes), or
             intermittent dexamethasone as an antiemetic

          -  No concurrent initiation of IV and/or oral bisphosphonates specifically for
             symptomatic bone metastases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Hauke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth C. Reed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <results_first_submitted>March 27, 2018</results_first_submitted>
  <results_first_submitted_qc>June 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Elizabeth Reed, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gefitinib Plus Etoposide</title>
          <description>Gefitinib plus etoposide: Gefitinib 250 mg p.o. daily, starting on Day 1 and taken on a continuous basis throughout the trial with Etoposide-50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).
Patients with stable disease will be treated for 2 additional cycles beyond maximum response, for a maximum of 6 cycles. Restaging will be performed every 2 cycles. After completion of treatment, patients will continue to be followed for survival.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gefitinib Plus Etoposide</title>
          <description>Gefitinib plus etoposide: Gefitinib 250 mg p.o. daily, starting on Day 1 and taken on a continuous basis throughout the trial with Etoposide-50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).
Patients with stable disease will be treated for 2 additional cycles beyond maximum response, for a maximum of 6 cycles. Restaging will be performed every 2 cycles. After completion of treatment, patients will continue to be followed for survival.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Number of subjects 19 years of age and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate as Measured by RECIST Criteria and PSA Criteria</title>
        <description>If there is at least 1 response, then 7 additional patients will be enrolled. If there are 4 or more responders overall, then the combination will be considered active and warrant further study. Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy.</description>
        <time_frame>Approximately 3 years</time_frame>
        <population>Fifteen subjects were evaluable. A total of 26 subjects were consented; two were screen failures. Nine subjects were not evaluable due to coming off study prior to reaching the point of evaluation (2 cycles).</population>
        <group_list>
          <group group_id="O1">
            <title>Gefitinib Plus Etoposide</title>
            <description>Gefitinib plus etoposide: Gefitinib 250 mg p.o. daily, starting on Day 1 and taken on a continuous basis throughout the trial with Etoposide-50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).
Patients with stable disease will be treated for 2 additional cycles beyond maximum response, for a maximum of 6 cycles. Restaging will be performed every 2 cycles. After completion of treatment, patients will continue to be followed for survival.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate as Measured by RECIST Criteria and PSA Criteria</title>
          <description>If there is at least 1 response, then 7 additional patients will be enrolled. If there are 4 or more responders overall, then the combination will be considered active and warrant further study. Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy.</description>
          <population>Fifteen subjects were evaluable. A total of 26 subjects were consented; two were screen failures. Nine subjects were not evaluable due to coming off study prior to reaching the point of evaluation (2 cycles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease (by RECIST criteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Responder (by PSA criteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers</title>
        <time_frame>At every cycle</time_frame>
        <population>Evaluation of this data is not possible as the investigator performing the analysis has left the study center prior to completing the analysis and data was not provided.</population>
        <group_list>
          <group group_id="O1">
            <title>Gefitinib Plus Etoposide</title>
            <description>Gefitinib plus etoposide: Gefitinib 250 mg p.o. daily, starting on Day 1 and taken on a continuous basis throughout the trial with Etoposide-50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).
Patients with stable disease will be treated for 2 additional cycles beyond maximum response, for a maximum of 6 cycles. Restaging will be performed every 2 cycles. After completion of treatment, patients will continue to be followed for survival.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers</title>
          <population>Evaluation of this data is not possible as the investigator performing the analysis has left the study center prior to completing the analysis and data was not provided.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gefitinib Plus Etoposide</title>
          <description>Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.
Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).
Gefitinib plus etoposide: Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient’s dose will be rounded to the nearest 50-mg multiple).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>Hemoglobin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <description>weakness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Acute renal failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>shortness of breath</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <description>Pulmonary embolism</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <description>deep vein thrombosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>hemoglobin</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralph Hauke, MD</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-354-8124</phone>
      <email>rhauke@nebraskacancer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

